Conexeu Sciences Inc CNXU
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Conexeu Sciences Shares Rise on Advancement of Tissue Restoration Platform
-
Conexeu Sciences Advances Ten Minute Tissue™ Toward Planned FDA 510(k) Submission
-
A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture
-
Conexeu Sciences Sets September and October 2026 Conference Schedule
-
Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration
-
Conexeu to Present at 2026 Controversies & Conversations in Laser & Cosmetic Surgery Symposium on the Role of the Extracellular Matrix in Tissue Regeneration
Trading Information
- Previous Close Price
- $2.83
- Day Range
- $2.43–2.85
- 52-Week Range
- $2.43–18.79
- Bid/Ask
- $2.69 / $2.81
- Shares Outstanding
- 30.83M
- Market Cap
- $78.31M
- Volume/Avg
- 518,841 / 278,230
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Conexeu Sciences Inc is an early-stage medical technology company. The company develops and supplies collagen-based technologies that helps doctors and patients regenerate tissue naturally, safely, and effectively. The company is focused on developing regenerative biomaterials that address relative needs in wound care, dentistry, and aesthetics. The company seek to provide physicians with device-based solutions that improve healing, restore soft tissue, and enhance patient outcomes across multiple clinical settings. The company focuses durable, and growing addressable markets in regenerative aesthetics, wound care, 3D-printed tissue structures, veterinary wound repair, and dental soft-tissue regeneration.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- https://www.conexeu.com
Valuation
|
Metric
|
CNXU
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 11.89 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CNXU
|
|---|---|
Quick Ratio | 1.55 |
Current Ratio | 5.31 |
Interest Coverage | — |
Quick Ratio
CNXU
Profitability
|
Metric
|
CNXU
|
|---|---|
Return on Assets (Normalized) | −176.31% |
Return on Equity (Normalized) | −199.11% |
Return on Invested Capital (Normalized) | −200.50% |
Return on Assets
CNXU
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|$S?&<^> | LOCK|?rH#@ | $142B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|P$Q<#Pw | LOCK|Q#M! | $96B | |||
| Moderna Inc
MRNA
| LOCK|$P!Dz<B | LOCK|zz | $89B | |||
| argenx SE ADR
ARGX
| LOCK|>S^%xP! | LOCK|!b | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|$Kr%ljr | LOCK|F@f | $43B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|%F^$#Sm< | LOCK|jjNk& | $30B | |||
| Incyte Corp
INCY
| LOCK|PC&g#y$ | LOCK|<! | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|<%dRqGC | LOCK|Cp? | $22B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Fz?RlS# | LOCK|&sBbL | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|qx?KR< | LOCK|Xmh | $15B |
United States